Back to GetFilings.com
FORM 10-Q
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
[ x ] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended: March 31, 2004
OR
[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from: _______ to _________
Commission File No.: 0-19974
ICU MEDICAL, INC.
(Exact name of Registrant as provided in charter)
-------------------------------------------------
Delaware 33-0022692
-------- ----------
(State or Other Jurisdiction of (I.R.S. Employer
Incorporation or Organization) Identification No.)
951 Calle Amanecer, San Clemente, California 92673
- -------------------------------------------- -----
(Address of Principal Executive Offices) (Zip Code)
(949) 366-2183
--------------
(Registrant's Telephone No. Including Area Code)
Indicate by check mark whether the registrant (1) has filed all reports to be
filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the
preceding 12 months (or for such shorter period that the registrant was required
to file such reports), and (2) has been subject to such filing requirements for
the past 90 days:
Yes [XXX] No [ ]
Indicate the number of shares outstanding in each of the issuer's classes of
common stock, as of the latest practicable date:
Class Outstanding at April 30, 2004
----- -----------------------------
Common 13,783, 441
ICU Medical, Inc.
Index
Part I - Financial Information Page Number
- ------------------------------ -----------
Item 1. Financial Statements (Unaudited)
- ------- --------------------------------
Condensed Consolidated Balance Sheets, March 31, 2004 and
December 31, 2003 3
Condensed Consolidated Statements of Income for the three months ended
March 31, 2004 and 2003 4
Condensed Consolidated Statements of Cash Flows for the three months ended
March 31, 2004 and 2003 5
Condensed Consolidated Statements of Comprehensive Income for the three
months ended March 31, 2004 and 2003 6
Notes to Condensed Consolidated Financial Statements 6
Item 2.
- -------
Management's Discussion and Analysis of Financial Condition and Results
of Operations 9
Item 3.
- -------
Quantitative and Qualitative Disclosures About Market Risk 20
Item 4.
- -------
Controls and Procedures 21
Part II - Other Information 22
- ---------------------------
Signatures 23
2
ICU Medical, Inc.
Condensed Consolidated Balance Sheets
March 31, 2004 and December 31, 2003
(all dollar amounts in thousands except per share data)
(unaudited)
ASSETS
3/31/04 12/31/03
---------- ----------
CURRENT ASSETS:
Cash and cash equivalents $ 3,798 $ 1,787
Liquid investments 81,950 71,350
---------- ----------
Cash, cash equivalents and liquid investments 85,748 73,137
---------- ----------
Accounts receivable, net of allowance for doubtful accounts of $685
and $742 as of March 31, 2004 and December 31, 2003, respectively 17,798 24,943
Finance loans receivable - current portion 3,789 4,142
Inventories 5,910 3,398
Prepaid income taxes -- 1,662
Prepaid expenses and other current assets 1,192 1,927
Deferred income taxes - current portion 2,052 2,008
---------- ----------
Total current assets 116,489 111,217
---------- ----------
PROPERTY AND EQUIPMENT, at cost: 73,045 71,615
Less--Accumulated depreciation (32,183) (30,574)
---------- ----------
40,862 41,041
---------- ----------
FINANCE LOANS RECEIVABLE - non-current portion 4,490 4,765
DEFERRED INCOME TAXES - non-current portion 2,716 2,680
INTANGIBLE ASSETS - net 4,073 4,166
OTHER ASSETS 410 419
---------- ----------
$ 169,040 $ 164,288
========== ==========
LIABILITIES AND STOCKHOLDERS' EQUITY
CURRENT LIABILITIES:
Accounts payable $ 3,053 $ 3,051
Accrued liabilities 5,242 5,234
---------- ----------
Total current liabilities 8,295 8,285
---------- ----------
STOCKHOLDERS' EQUITY:
Convertible preferred stock, $1.00 par value
Authorized -- 500,000 shares, issued and outstanding -- none -- --
Common stock, $0.10 par value-
Authorized -- 80,000,000 shares, issued -- 14,158,612 1,416 1,416
Additional paid-in capital 63,294 63,535
Treasury stock, at cost -- 441,875 and 471,390 shares at
March 31, 2004 and December 31, 2003, respectively (11,210) (12,116)
Retained earnings 107,131 102,991
Accumulated other comprehensive income 114 177
---------- ----------
Total stockholders' equity 160,745 156,003
---------- ----------
$ 169,040 $ 164,288
========== ==========
The accompanying notes are an integral part of
these consolidated financial statements.
3
ICU MEDICAL, INC.
Condensed Consolidated Statements of Income
For the Three Months Ended
March 31, 2004 and March 31, 2003
(all dollar amounts in thousands except share data)
(unaudited)
For the Three Months Ended
------------------------------
3/31/04 3/31/03
------------ ------------
REVENUES:
Net sales $ 21,270 $ 28,736
Other 963 2,040
------------ ------------
TOTAL REVENUE 22,233 30,776
COST OF GOODS SOLD 9,813 13,024
------------ ------------
Gross profit 12,420 17,752
------------ ------------
OPERATING EXPENSES:
Selling, general and administrative 5,655 6,087
Research and development 451 471
------------ ------------
Total operating expenses 6,106 6,558
------------ ------------
Income from operations 6,314 11,194
INVESTMENT INCOME 310 296
------------ ------------
Income before income taxes 6,624 11,490
PROVISION FOR INCOME TAXES 2,484 4,420
------------ ------------
NET INCOME $ 4,140 $ 7,070
============ ============
NET INCOME PER SHARE
Basic $ 0.30 $ 0.50
Diluted $ 0.28 $ 0.46
WEIGHTED AVERAGE NUMBER OF SHARES
Basic 13,699,991 14,007,731
Diluted 15,041,285 15,337,366
The accompanying notes are an integral part of
these consolidated financial statements.
4
ICU Medical, Inc.
Condensed Consolidated Statements of Cash Flows
For the Three Months Ended
March 31, 2004 and March 31, 2003
(all dollar amounts in thousands)
(unaudited)
For the Three Months Ended
------------------------
3/31/04 3/31/03
--------- ---------
CASH FLOWS FROM OPERATING ACTIVITIES:
Net Income $ 4,140 $ 7,070
Adjustments to reconcile net income to net cash
provided by operating activities --
Depreciation and amortization 1,696 1,633
Net change in current operating assets and liabilities,
net of effects of acquisitions 6,892 (4,060)
--------- ---------
12,728 4,643
Tax benefits from exercise of stock options 122 3
--------- ---------
Net cash provided by operating activities 12,850 4,646
--------- ---------
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of property and equipment (1,410) (3,017)
Cash paid for acquisitions -- (1,221)
Advances under finance loans (1,000) (2,152)
Proceeds from finance loan repayments 1,628 501
Purchases of investments (10,600) --
Proceeds from sale of investments -- 9,575
--------- ---------
Net cash provided by (used in) investing activities (11,382) 3,686
--------- ---------
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from exercise of stock options 264 10
Proceeds from employee stock purchase plan 279 271
Purchase of treasury stock -- (8,649)
--------- ---------
Net cash provided by (used in) financing activities 543 (8,368)
--------- ---------
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS 2,011 (36)
CASH AND CASH EQUIVALENTS, beginning of the period 1,787 4,165
--------- ---------
CASH AND CASH EQUIVALENTS, end of the period $ 3,798 $ 4,129
========= =========
The accompanying notes are an integral part of
these consolidated financial statements.
5
ICU Medical, Inc.
Condensed Consolidated Statements of Comprehensive Income
For the Three Months Ended
March 31, 2004 and March 31, 2003
(all dollar amounts in thousands except share data)
(unaudited)
For the Three Months Ended
------------------------
3/31/04 3/31/03
-------- --------
Net income $ 4,140 $ 7,070
Other comprehensive income, net of tax:
Foreign currency translation adjustment (63) --
-------- --------
Comprehensive income $ 4,077 $ 7,070
======== ========
ICU Medical, Inc.
Notes to Condensed Consolidated Financial Statements
March 31, 2004
(All dollar amounts in tables in thousands except per share data)
(unaudited)
NOTE 1: BASIS OF PRESENTATION: The accompanying unaudited interim condensed
consolidated financial statements have been prepared in accordance with
accounting principles generally accepted in the United States of America and
pursuant to the rules and regulations of the Securities and Exchange Commission
and reflect all adjustments, which consist of only normal recurring adjustments,
which are, in the opinion of Management, necessary to a fair statement of the
consolidated results for the interim periods presented. Results for the interim
period are not necessarily indicative of results for the full year. Certain
information and footnote disclosures normally included in consolidated financial
statements prepared in accordance with generally accepted accounting principles
have been condensed or omitted pursuant to such rules and regulations. The
condensed consolidated financial statements should be read in conjunction with
the consolidated financial statements and notes thereto included in our 2003
Annual Report to Stockholders.
ICU Medical, Inc. (the "Company," a Delaware corporation) operates
principally in one business segment engaged in the development, manufacturing
and marketing of disposable medical devices designed to protect healthcare
workers and patients from the spread of infectious diseases. The Company's
devices are sold principally to distributors and medical product manufacturers
throughout the United States and a small portion internationally. All
subsidiaries are wholly owned and are included in the consolidated financial
statements. All intercompany balances and transactions have been eliminated.
6
NOTE 2: INVENTORIES consisted of the following:
3/31/04 12/31/03
------- --------
Raw material $ 3,139 $ 2,699
Work in process 579 340
Finished goods 2,192 359
--------------- ---------------
Total $ 5,910 $ 3,398
=============== ===============
NOTE 3: PROPERTY AND EQUIPMENT, at cost, consisted of the following:
3/31/04 12/31/03
------- --------
Land, building and building
improvements $21,321 $16,887
Machinery and equipment 29,437 26,429
Furniture and fixtures 7,031 6,572
Molds 11,524 11,480
Construction in process 3,732 10,247
--------------- ---------------
Total $73,045 $71,615
=============== ===============
NOTE 4: FINANCE LOANS RECEIVABLE are commercial loans by ICU Finance, Inc., a
wholly-owned consolidated subsidiary. Loans are made only to credit-worthy
healthcare entities and are fully secured by real and personal property. We plan
to hold the loans to maturity or payoff. They are carried at their outstanding
principal amount, and will be reduced for an allowance for credit losses and
charge offs if any such reductions are determined to be necessary in the future.
Interest is accrued as earned based on the stated interest rate and amounts
outstanding. Loan fees and costs have not been material. Scheduled maturities
are: remainder of 2004 $3,413,000; 2005 $1,228,000; 2006 $1,191,000; 2007
$1,168,000 and 2008 $1,279,000. Weighted average maturity (principal and
interest) at March 31, 2004 was 1.5 years and the weighted average interest rate
was 5.5%. In October 2003, we discontinued new lending activities; we will honor
existing lending commitments. The maximum that can be borrowed under all
commitments, including amounts outstanding, was approximately $8,500,000 at
March 31, 2004.
NOTE 5: NET INCOME PER SHARE is computed by dividing net income by the weighted
average number of common shares outstanding. Diluted earnings per share is
computed by dividing net income by the weighted average number of common shares
outstanding plus dilutive securities. Dilutive securities are outstanding common
stock options (excluding stock options with an exercise price in excess of
market value), less the number of shares that could have been purchased with the
proceeds from the exercise of the options, using the treasury stock method, and
were 1,341,294 and 1,329,635 for the three months ended March 31, 2004 and 2003,
respectively. Options that are antidilutive because their average exercise price
exceeded the average market price of our common stock for the period
approximated 540,000 and none for the three months ended March 31, 2004 and
2003, respectively.
NOTE 6: STOCK OPTIONS: We account for our stock options granted to employees and
directors under Accounting Principles Board ("APB") Opinion No. 25 "Accounting
for Stock Issued to Employees" and related interpretations as permitted by SFAS
No. 123 "Accounting for Stock-Based Compensation," and do not recognize
compensation expense because the exercise price of the options equals the fair
market value of the underlying shares at the date of grant or, as to the 2002
Employee Stock Purchase Plan, the plan is non-compensatory under the provisions
of APB Opinion No. 25. Under SFAS No. 123, the Company is required to present
certain pro forma earnings information determined as if employee stock options
were accounted for under the fair value method of that Statement. The fair value
7
for options granted in the first quarter of 2004 and 2003 was estimated as of
the date of grant using a Black-Scholes option pricing model. The Black-Scholes
option valuation model was developed for use in estimating fair value of fully
transferable traded options with no vesting restrictions, and, similar to other
option valuation models, requires use of highly subjective assumptions,
including expected stock price volatility. The characteristics of our stock
options differ substantially from those of traded stock options, and changes in
the subjective assumptions can materially affect estimated fair values;
therefore, in Management's opinion, existing option valuation models do not
necessarily provide a reliable single measure of the fair value of our stock
options. The following information is provided pursuant to SFAS No. 123, as
amended. The pro forma adjustment reflects stock-based compensation cost
calculated under the fair value method, net of related tax effects, pursuant to
SFAS No. 123.
Quarter ended March 31,
2004 2003
------- -------
Net Income, as reported.......... $4,140 $7,070
Pro forma adjustment............. 1,020 1,342
------- -------
Net Income, pro forma............ $3,120 $5,728
======= =======
Net Income per share.............
Basic, as reported $0.30 $0.50
Diluted, as reported $0.28 $0.46
Basic, pro forma $0.23 $0.42
Diluted, pro forma $0.21 $0.38
NOTE 7: INCOME TAXES: The effective tax rate differs from that computed at the
federal statutory rate of 35% principally because of the effect of state income
taxes partially offset by the effect of tax-exempt investment income.
NOTE 8: MAJOR CUSTOMERS: We had revenues equal to ten percent or greater of
total net revenues from one customer, Hospira, Inc. (formerly a part of Abbott
Laboratories), of 60% and 68% in the first quarters of 2004 and 2003,
respectively.
NOTE 9: COMMITMENTS AND CONTINGENCIES: We are from time to time involved in
various legal proceedings, either as a defendant or plaintiff, most of which are
routine litigation in the normal course of business. We believe that the
resolution of the legal proceedings in which we are involved will not have a
material adverse effect on our financial position or results of operations.
In the normal course of business, we have agreed to indemnify officers
and directors of the Company to the maximum extent permitted under Delaware law
and to indemnify customers as to certain intellectual property matters related
to sales of our products. There is no maximum amount limit on the
indemnification that may be required under these agreements. We have never
incurred, nor do we expect to incur, any liabilities for indemnification.
NOTE 10: ACQUISITIONS: In June 2003, we acquired the assets of two affiliated
manufacturers of intravenous therapy systems located in northern Italy for a
cash payment of approximately $4.6 million. Principal assets acquired are
assembly facilities and related equipment of $2,443,000 and inventories of
$1,110,000 and an agreement not to compete valued at approximately $818,000. The
acquired assets and related operating results are included in our consolidated
financial statements since June 30, 2003. Their effect on our financial
statements is immaterial.
8
Management's Discussion and Analysis of Financial Condition
and Results of Operations
We are a leader in the development, manufacture and sale of
proprietary, disposable medical connection systems for use in intravenous
("I.V.") therapy applications. Our devices are designed to protect healthcare
workers and their patients from exposure to infectious diseases such as
Hepatitis B and C and Human Immunodeficiency Virus ("HIV") through accidental
needlesticks. We are also a leader in the production of custom I.V. systems and
low cost generic I.V. systems and we incorporate our proprietary products on
many of those custom I.V. systems. We also manufacture and sell the
Punctur-Guard line of blood collection needles, which we acquired in October
2002.
Critical Accounting Policies
Our significant accounting policies are summarized in Note 1 to the
Consolidated Financial Statements included in our 2003 Annual Report to
Shareholders. In preparing our financial statements, we make estimates and
assumptions that affect the expected amounts of assets and liabilities and
disclosure of contingent assets and liabilities. We apply our accounting
policies on a consistent basis. As circumstances change, they are considered in
our estimates and judgments, and future changes in circumstances could result in
changes in amounts at which assets and liabilities are recorded.
Investment securities are all marketable and considered "available for
sale". See Item 3. Quantitative and Qualitative Disclosures about Market Risk.
Under our current investment policies, the securities in which we invest have no
significant difference between cost and fair value. If our investment policies
were to change, and there were differences between cost and fair value, that
difference, net of tax effect, would be reflected as a separate component of
stockholders' equity.
We record sales and related costs when ownership of the product
transfers to the customer. Under the terms of most purchase orders, ownership
transfers on shipment, but in some cases it transfers on delivery. If there are
significant doubts at the time of shipment as to the collectibility of the
receivable, we defer recognition of the sale in revenue until the receivable is
collected. Most of our customers are medical product manufacturers or
distributors, although some are end-users. Our only post-sale obligations are
warranty and certain rebates. We warrant products against defects and have a
policy permitting the return of defective products. We record warranty returns
as an expense; amounts have been insignificant. Customers, with certain
exceptions, do not retain any right of return and there is no price protection
with respect to unsold products; returns from customers with return rights have
not been significant. We accrue rebates as a reduction in revenue based on
contractual commitments and historical experience. Adjustments of estimates of
warranty claims, rebates or returns, which have not been, and are not expected
to be material, affect current operating results when they are determined.
Accounts receivable are stated at net realizable value. An allowance is
provided for estimated collection losses based on specific past due accounts for
which we consider collection to be doubtful. Loss exposure is principally with
international distributors for whom normal payment terms are long in comparison
to those of our other customers and, to a lesser extent, domestic distributors.
Many of these distributors are relatively small and we are vulnerable to adverse
developments in their businesses that can hinder our collection of amounts due.
If actual collection losses exceed expectations, we could be required to accrue
additional bad debt expense, which could have an adverse effect on our operating
results in the period in which the accrual occurs.
9
Inventories are stated at the lower of cost or market. We need to carry
many components to accommodate our rapid product delivery, and if we misestimate
demand or if customer requirements change, we may have components in inventory
that we may not be able to use. Most finished products are made only after we
receive orders except for certain standard (non-custom) products which we will
carry in inventory in expectation of future orders. For finished products in
inventory, we need to estimate what may not be saleable. We regularly review
inventory for slow moving items and write off all items we do not expect to use
in manufacturing, or finished products we do not expect to sell. If actual usage
of components or sales of finished goods inventory is less than our estimates,
we would be required to write off additional inventory, which could have an
adverse effect on our operating results in the period in which the write-off
occurs.
Property and equipment is carried at cost and depreciated on the
straight-line method over the estimated useful lives. The estimates of useful
lives are significant judgments in accounting for property and equipment,
particularly for molds and automated assembly machines that are custom made for
us. We may retire them on an accelerated basis if we replace them with larger or
more technologically advanced tooling. The remaining useful lives of all
property and equipment are reviewed regularly and lives are adjusted or assets
written off based on current estimates of future use. As part of that review,
property and equipment is reviewed for other indicators of impairment, but to
date we have not encountered circumstances indicating the carrying amount of an
asset, or group of assets, may not be recoverable. An unexpected shortening of
useful lives of property and equipment that significantly increases depreciation
provisions, or other circumstances causing us to record an impairment loss on
such assets, could have an adverse effect on our operating results in the period
in which the related charges are recorded.
New Accounting Pronouncements
We have implemented all new accounting pronouncements that are in
effect and that may impact our consolidated financial statements and do not
believe that there are any other new accounting pronouncements that have been
issued that might have a material impact on our consolidated financial
statements.
Business Overview
Until the late 1990s, our primary emphasis in product development,
sales and marketing was disposable medical connectors for use in I.V. therapy,
and our principal product was the CLAVE. In the late 1990s, we commenced a
transition from a product-centered company to an innovative, fast, efficient,
low-cost manufacturer of custom I.V. systems, using processes that we believe
can be readily applied to a variety of disposable medical devices. This strategy
enables us to capture revenue on the entire I.V. system, and not just a
component of the system.
We are also increasing our efforts to acquire new products. We acquired
the Punctur-Guard line of blood collection needles in 2002 and are continuing to
seek other opportunities. However, there can be no assurance that we will be
successful in finding acquisition opportunities, or in acquiring companies or
products.
Custom I.V. systems and new products will be of increasing importance
to us in future years. We expect CLAVE products to continue to grow in the U.S.,
but at a slower percentage growth rate than in the past because of our large
market penetration. Growth for all of our products outside the U.S. could be
substantial, although to date it has been modest. Therefore, we will be
directing increasing product development, acquisition, sales and marketing
efforts to custom I.V. systems and new products in the U.S. and increasing our
emphasis on the markets outside the U.S.
10
Our largest customer has been Abbott Laboratories ("Abbott"). On April
30, 2004, Abbott spun off its core Hospital Products Division to its
stockholders as an independent company named Hospira, Inc. The Hospital Products
Division historically accounted for virtually all of our sales to Abbott. Abbott
has assigned our agreements with Abbott to Hospira. We believe the spin-off is a
positive development for us and will result in new business opportunities with
Hospira. For clarity, all historical references to Abbott and its Hospital
Products Division have been changed to Hospira.
Our relationship with Hospira has been and will continue to be of
singular importance to our growth. In 2003, approximately 67% of our revenue was
from sales to Hospira, and we expect this percentage to increase on a yearly
basis in the future. Hospira has a significant share of the I.V. set market in
the U.S., and provides us access to that market. We expect that Hospira will be
important to our growth for CLAVE, custom I.V. systems, and our other products
in the U.S. and also outside the U.S.
We believe that achievement of our growth objectives, both within the
U.S., and outside the U.S., will require increased efforts by us in sales and
marketing and product development, and we expect to increase expenditures for
those during 2004.
There is no assurance that we will be successful in implementing our
growth strategy. The custom I.V. systems market is still small and we could
encounter customer resistance to custom products. Further, we could encounter
increased competition as other companies see opportunity. Product development or
acquisition efforts may not succeed, and even if we do develop or acquire
products, there is no assurance that we will achieve profitable sales of such
products. An adverse change in our relationship with Hospira, or a deterioration
of Hospira's position in the market, could have an adverse effect on us.
Increased expenditures for sales and marketing and product acquisition and
development may not yield desired results when expected, or at all. While we
have taken steps to control all these risks, there are certain of those risks
which may be outside of our control, and there is no assurance that steps we
have taken will succeed.
Overview of Operations
The following table sets forth the net revenues by product as a
percentage of total net sales for the periods indicated:
=========================================================================================================
Product Line 2001 2002 2003 Q1-03 Q1-04
- ---------------------------------------------------------------------------------------------------------
CLAVE 74% 67% 59% 63% 50%
- ---------------------------------------------------------------------------------------------------------
Custom and Generic I.V. Systems 13% 17% 22% 16% 29%
- ---------------------------------------------------------------------------------------------------------
Punctur-Guard(R) - 1% 7% 6% 7%
- ---------------------------------------------------------------------------------------------------------
CLC2000(R) 3% 4% 4% 4% 4%
- ---------------------------------------------------------------------------------------------------------
Other Products 10% 7% 4% 4% 6%
- ---------------------------------------------------------------------------------------------------------
License, royalty and revenue share - 4% 4% 7% 4%
- ---------------------------------------------------------------------------------------------------------
Total 100% 100% 100% 100% 100%
=========================================================================================================
Most custom I.V. systems include one or more CLAVEs. Total CLAVE sales
including custom I.V. systems with at least one CLAVE were 75% of net revenue in
the first quarter of 2003 and 69% of net revenue in the first quarter of 2004.
11
We sell our products to independent distributors and through agreements
with Hospira (the "Hospira Agreements") and certain other medical product
manufacturers. Most independent distributors handle the full line of our
products. Hospira purchases CLAVE products, principally bulk, non-sterile
connectors, and the CLC2000. In addition, we sell custom I.V. systems to Hospira
under a program referred to as SetSource. In January 2004, we announced the
execution of amendments to our existing agreements with Hospira. The amendments
extend the terms of our agreements to 2014 and provide Hospira with rights to
distribute all existing ICU Medical products worldwide. We signed another
contract amendment with Hospira in January 2004 to distribute our Punctur-Guard
line of blood collection needles in the U.S. and the rest of the world. We also
sell certain other products to a number of other medical product manufacturers.
We believe that as healthcare providers continue to either consolidate
or join major buying organizations, our success in marketing and distributing
CLAVE products will depend, in part, on our ability, either independently or
through strategic relationships such as our Hospira relationship, to secure
long-term CLAVE contracts with large healthcare providers and major buying
organizations. As a result of this marketing and distribution strategy we derive
most of our revenues from a relatively small number of distributors and
manufacturers. The loss of a strategic relationship with a customer or a decline
in demand for a manufacturing customer's products could have a material adverse
effect on our operating results.
We believe the success of the CLAVE has motivated, and will continue to
motivate others to develop one-piece, swabbable, needleless connectors that may
incorporate many of the same functional and physical characteristics as the
CLAVE. We are aware of a number of such products. In response to competitive
pressure, we have been reducing prices to protect and expand our market,
although overall pricing has been stable recently. The price reductions to date
have been more than offset by increased volume. We expect that the average price
of our CLAVE products may continue to decline. There is no assurance that our
current or future products will be able to successfully compete with products
developed by others.
The federal Needlestick Safety and Prevention Act, enacted in November
2000, modified standards promulgated by the Occupational Safety and Health
Administration to require employers to use safety I.V. systems where appropriate
to reduce risk of injury to employees from needlesticks. We believe this law has
had and will continue to have a positive effect on sales of our needleless
systems and blood collection needles, although we are unable to quantify the
current or anticipated effect of the law on our sales.
We are taking steps to reduce our dependence on our current proprietary
products. We are seeking to substantially expand our custom I.V. systems
business through increased sales to medical product manufacturers and
independent distributors. Under one of our Hospira Agreements, we manufacture
all new custom I.V. sets for sale by Hospira and jointly promote the products
under the name SetSource. We expect continuing significant increases in sales of
custom I.V. systems under this agreement. We also contract with group purchasing
organizations and independent dealer networks for inclusion of our products
among those available to members of those entities. Custom I.V. systems
accounted for approximately $6.6 million of net sales in the first three months
of 2004, including net sales under the Hospira SetSource program of
approximately $2.7 million. Also, in the fourth quarter of 2002 we acquired
Bio-Plexus. Inc., whose principal products are blood collection needles, under
the Punctur-Guard name, that are designed to eliminate exposure to sharp,
contaminated needles. Punctur-Guard product revenues in the first quarter of
2004 were $1.5 million. There is no assurance that either one of these
initiatives will continue to succeed.
We have an ongoing program to increase systems capabilities, improve
manufacturing efficiency, reduce labor costs, reduce time needed to produce an
order, and minimize investment in inventory. These include use of automated
assembly equipment for new products and other products for which volume is
growing, use of larger molds and molding machines, centralization of all
proprietary molding in San Clemente, expansion of our production facility in
Mexico, and the establishment of other production facilities outside the U.S.
12
We distribute products through three distribution channels. Net product
revenues for each distribution channel were as follows:
======================================================================================================
Channel 2001 2002 2003 Q1-03 Q1-04
- ------------------------------------------------------------------------------------------------------
Medical product manufacturers 72% 73% 71% 75% 65%
- ------------------------------------------------------------------------------------------------------
Independent domestic distributors 20% 19% 23% 21% 26%
- ------------------------------------------------------------------------------------------------------
International 8% 8% 6% 4% 9%
- ------------------------------------------------------------------------------------------------------
Total 100% 100% 100% 100% 100%
======================================================================================================
QUARTER-TO-QUARTER COMPARISONS: We present summarized income statement
data in Item 1. Financial Statements. The following table shows, for the year
2003 and the first quarters of 2003 and 2004, the percentages of each income
statement caption in relation to revenues, and the percentage change in each
caption in each quarter. (We currently calculate our gross profit percentage
based on net sales, which includes only product sales and excludes non-product
revenue such as license fees. (See below for more information on non-product
revenue. We present the alternative calculation based on total revenue for the
convenience of readers who prefer to view it that way).
Percentage of Revenues Changes
------------------------------------ -------------------
2003 Q1-03 Q1-04 Q1-04 v. Q1-03
---- ----- ----- --------------
Revenue
Net sales 96% 93% 96% -26%
Other 4% 7% 4% -53%
------------------------------------ -------------------
Total revenues 100% 100% 100% -28%
Cost of sales 47% 45% 46% -25%
Gross Profit
Percentage of net sales 53% 55% 54% -27%
Percentage of all revenues 55% 58% 56% -30%
Selling, general and administrative expenses 21% 20% 25% -8%
Research and development expenses 2% 1% 2% -4%
------------------------------------ -------------------
Total operating expenses 23% 21% 27% -8%
Income from operations 32% 36% 29% -43%
------------------------------------ -------------------
Investment income 1% 1% 1% 0.5%
------------------------------------ -------------------
Income before income taxes 33% 37% 30% -42%
Income taxes 12% 14% 11% -44%
------------------------------------ -------------------
Net income 21% 23% 19% -41%
==================================== ===================
13
QUARTERLY RESULTS: The healthcare business in the United States is
subject to seasonal fluctuations, and activity tends to diminish somewhat in the
summer months of June, July and August, when illness is less frequent than in
winter months and patients tend to postpone elective procedures. This typically
causes seasonal fluctuations in our business. In addition, we can experience
fluctuations in net sales as a result of variations in the ordering patterns of
our largest customers, which may be driven more by production scheduling and
their inventory levels, and less by seasonality. Our expenses often do not
fluctuate in the same manner as net sales, which may cause fluctuations in
operating income that are disproportionate to fluctuations in our revenue.
QUARTER ENDED MARCH 31, 2004 COMPARED TO THE QUARTER ENDED MARCH 31, 2003
- -------------------------------------------------------------------------
Net revenues decreased $8,543,000, or approximately 28%, to $22,233,000
in the first quarter of 2004 compared to $30,776,000 during the same period last
year. Approximately $5.7 million of the decrease is attributable to two items
that occurred in the first quarter of 2003 but did not recur in the 2004
quarter; a deferment of approximately $4.0 million of CLAVE product available
for delivery to Hospira on current orders in the fourth quarter of 2002, but for
which shipment was deferred until early 2003 by agreement with Hospira, and a
one-time license fee of approximately $1.7 million. The balance of the decrease,
representing only a 9.5% decrease, is primarily attributable to the timing of
orders from customers.
DISTRIBUTION CHANNELS: Net sales to Hospira in the first quarter of
2004 were $13,159,000, as compared to net sales of $20,705,000 in the first
quarter of 2003. (Hospira sales discussed in this paragraph do not include
export sales.) Net sales of CLAVE products to Hospira, excluding custom CLAVE
I.V. systems, in the first quarter of 2004 decreased approximately 48%, to
$8,994,000 due to a decrease in unit volume in part because Hospira reduced its
inventory of CLAVE products and in parat because there was nothing comparable in
2004 to this deferment of approximately $4.0 million of CLAVE orders to the
first quarter of 2003. We do not believe Hospira's unit sales to their customers
has declined. Sales to Hospira under the SetSource program were $2,744,000, as
compared with approximately $2,080,000 in the first quarter of 2003. We expect
increases in CLAVE unit and dollar sales volume with Hospira for the full year
2004 as compared with 2003, as well as a significant increase in SetSource unit
and sales volume as we continue to grow this market. Net sales of CLC2000
increased approximately 22% to $512,000 on increased unit volume. We expect
sales of the CLC2000 to Hospira will increase in the future. Net sales of the
Rhino were down 13% to approximately $414,000; sales of Rhino started to decline
in early 2001, and we expect them to decline in the future as the market shifts
to one piece, swabbable, needleless technology. There is no assurance as to the
amount of any future sales increases to Hospira.
Net sales to independent domestic distributors decreased approximately
10% from $6,378,000 in the first quarter of 2003 to $5,766,000 in 2004; this
decrease in net sales was generally due to the timing of orders and their
fulfillment, as unit volume sold by distributors showed an increase in the first
quarter of 2004 as compared with the first quarter of 2003. This decrease in
sales to independent distributors is attributed to a $608,000, or 44% decrease
in CLAVE product sales to $785,000 and a $261,000, or 17%, decrease in sales of
Punctur-Guard products, and a decrease in sales of CLC2000 and the Lopez Valve
of 48% and 21%, respectively, on lower unit volume. These decreases were
partially offset by a 20% increase in our custom I.V. system sales from
approximately $2,545,000 to approximately $3,060,000 (this includes all custom
I.V. systems, including custom I.V. systems that include CLAVE connectors). The
increase in sales of custom I.V. systems was attributable to an increase in unit
volume, and we expect increased volume of custom I.V. systems in the future as
we continue to penetrate this market. As part of our program to increase sales
of custom I.V. systems, we have been encouraging customers to purchase custom
I.V. systems that include CLAVE connectors, rather than purchasing only the
CLAVE connectors. This has contributed to a drop in CLAVE product sales and an
increase in custom I.V. systems including one or more CLAVEs. Sales of custom
I.V. systems including one or more CLAVE connectors and CLAVE products combined
were $2,938,000 in the first quarter of 2003 as compared with $2,855,000 in the
first quarter of 2004. The decrease in Punctur-Guard products was due to pricing
concessions on our Punctur-Guard line of products to achieve wider distribution.
There is no assurance as to the amount of any future sales increases to the
independent domestic distributors.
14
Net sales to international distributors (excluding Canada) increased
approximately 70% and were $2,060,000 in the first quarter of 2004, as compared
with $1,210,000 in the first quarter of 2003. The increase was primarily due to
a 94% increase in CLAVE products on increased unit volume. In 2003, we
experienced a slowing of distributor orders while they reduced CLAVE inventory
levels. Orders in most areas of the world have returned to more normal levels,
and this and expansion of our business accounted for the increase in CLAVE
sales. We expect increases in foreign sales in the future in response to
increased sales and marketing efforts including additional business development
managers. Also, we believe we will see a positive impact beginning late in 2004
or 2005 from our recent amendments to the Hospira contracts. There is no
assurance that those expectations will be realized.
PRODUCT AND OTHER REVENUE: Net sales of CLAVE products (excluding
custom CLAVE I.V. systems) decreased to $11,136,000 in the first quarter of 2004
from $19,527,000 in the first quarter of 2003, or 43%. Net sales of CLAVE
products including custom I.V. systems with CLAVE decreased from $22,575,000 in
the first quarter of 2003 to $15,445,000 in the first quarter of 2004, or 32%.
This decrease was due primarily to a decrease in unit shipments of CLAVE
products to Hospira and our domestic distributors, offset by an increase in unit
shipments to our international distributors. The aggregate average net selling
price of CLAVE products in the first quarter of 2004 changed little from 2003
except for a decrease in selling prices to specialty distributors, and we do not
expect any more than minimal decreases for the balance of the year. We expect
growth in CLAVE unit and dollar sales volume in 2004 because of the growth that
we expect in all of our distribution channels. However, there is no assurance
that the expectations will be realized.
Net sales of custom and generic I.V. systems were $6,134,000 in the
first quarter of 2004 compared to $4,894,000 in the first quarter of 2003, a
$1,240,000, or 25%, increase. The SetSource program with Hospira accounted for
about 54% of the increase, with most of the balance in sales to independent
domestic and international distributors. Unit volume accounted for the majority
of the increase.
We acquired the Punctur-Guard product line and technology with the
purchase of Bio-Plexus on October 31, 2002. After our acquisition of Bio-Plexus
on October 31, 2002, we made significant improvements to the Punctur-Guard
products and manufacturing processes. We did not actively promote sales of those
products until completion of those product improvements. We completed
improvements on the Winged Set products and re-launched them on March 1, 2003.
We completed improvements on the BCN and started selling the improved product in
late September 2003. Sales of Punctur-Guard products were $1,468,000 in the
first quarter of 2004 compared to $1,548,000 for the first quarter of 2003. The
reduction in sales was because of pricing concessions to achieve wider
distribution. We expect sales of these products to increase in the future, but
we give no assurance that such increases will be achieved.
Net sales of the CLC2000 were $943,000 in the first quarter of 2004, a
$223,000 or 19% decrease over the first quarter of 2003 principally because of a
decrease in sales to independent domestic and international distributors,
partially offset by an increase in sales to Hospira. We expect sales of the
CLC2000 to increase moderately in 2004 and later years, but there is no
assurance as to the amount or timing of future CLC2000 sales.
Other revenue consists of license, royalty and revenue share income.
The principal ongoing components are royalties received for other companies' use
of Punctur-Guard technology, SafeLine revenue share payments from B. Braun and
payments under another license of approximately $235,000 per quarter for four
years starting in the first quarter of 2004. In the first quarter of 2003, we
received payment for a fully paid up license to use certain of our patents of
$1,666,000; the absence of a similar payment in 2004, partially offset by
increases in other payments, led to the $1,077,000 decrease on Other Income. We
may receive other license fees or royalties in the future for the use of our
technology. We give no assurance as to amounts or timing of any future payments,
or whether such payments will be received.
15
GROSS MARGIN for the first quarter of 2004, calculated on net sales and
excluding other revenue, was 54% as compared with 55% for the first quarter of
2003. The decrease was because of the effect of our Punctur-Guard operations and
the new facility in Italy. Punctur-Guard and the new facility in Italy reduced
the gross margin by 5 percentage points, otherwise the Company, excluding these
recent acquisitions, had a gross margin of 59%. We are working to improve gross
margins on the Punctur-Guard products; improvement will depend on increased
sales and full conversion of this product line to our manufacturing techniques.
We anticipate that those improvements will result in a modest increase in the
gross margin in 2004, but we do not expect it to reach our "benchmark" level of
57% in 2004. We give no assurance as to the amount or timing of future
improvements to our gross margins.
SELLING, GENERAL AND ADMINISTRATIVE EXPENSES ("SG&A") in the first
quarter of 2004 decreased by $432,000, or 7%, to $5,655,000, and were 25% of
revenue as compared with 20% in 2003 on higher revenue. The decrease in costs
was primarily due to the elimination of general and administrative costs related
to Bio-Plexus and a reduction in litigation costs, partially offset by increased
corporate administrative costs and administrative costs in our new operation in
Italy. Selling costs were flat compared to the first quarter of 2003 but we
expect to add sales personnel as 2004 progresses, and those personnel and
related costs will cause a modest increase in total SG&A costs for 2004.
However, actual costs may differ from our expectations.
RESEARCH AND DEVELOPMENT EXPENSES ("R&D") in total were relatively
unchanged in the first quarter of 2004 as compared with the first quarter of
2003. Spending was principally on new product development, with a smaller amount
being spent on product improvements to Punctur-Guard. Spending on software
development decreased as principal development projects reached completion. We
estimate that R&D costs will increase during 2004 to support on-going new
product development and various product and process improvements. However, R&D
costs could differ from these estimates and the R&D may not be completed as
expected.
We plan to launch, in limited markets, a new connector in 2004. We have
applied to the Food & Drug Administration ("FDA") under Section 510(k) of the
Federal Food, Drug and Cosmetics Act for approval to market this new connector.
We also expect to launch a new product for the diabetes market for which we have
already received marketing approval from the FDA under section 510(k) and which
we expect to introduce within the next six months. We are currently developing a
new integral check valve for use with all standard and custom I.V.
administration sets, which we expect to introduce in the next six months. There
is no assurance that the FDA will grant any required marketing clearance, that
we will launch any of these new products, or that they will achieve sales if and
when we commence marketing them.
INCOME FROM OPERATIONS decreased $4,388,000 or 43% and was 29% of total
revenue in the first quarter of 2004 as compared with 36% in the first quarter
of 2003. The decline in income from operations as a percentage of revenue was
because of a decline in revenue of 28%, a decrease in the gross profit as a
percentage of sales, partially offset by an 8% decrease in operating expenses.
INVESTMENT INCOME increased by $14,000 in the first quarter of 2004 as
compared with the first quarter of 2003 because of a small increase in invested
funds (including finance loans) partially offset by a slight decease in overall
yield.
INCOME TAXES were accrued at an effective tax rate of 37.5% in the
first quarter of 2004, as compared with 38.5% in the first quarter of 2003. The
decrease is principally because of savings in state income taxes due to
effective state tax planning. We expect our effective tax rate will be
approximately 37.5% for the entire year 2004.
16
NET INCOME decreased 41% to $4,140,000 in the first quarter of 2004 as
compared with $7,070,000 in the first quarter of 2003. While revenues decreased
28%, gross profit decreased 30%. Operating expenses decreased less than that,
8%, but because that decrease was less than the percentage decrease in gross
margin, income from operations decreased 43%. The slight increase in investment
income and a decrease in the effective income tax rate resulted in an overall
decrease of 41%. Net income per share - diluted decreased $0.19 or 40%, in the
first quarter of 2004 over the first quarter of 2003. The percentage decrease in
earnings per share was less than that of net income because there were fewer
shares outstanding due to our stock repurchase of common shares with
approximately the same number of dilutive shares during each quarter.
LIQUIDITY AND CAPITAL RESOURCES
- -------------------------------
During the first three months of 2004, our working capital increased
$5,262,000 to $108,194,000 from $102,932,000 at December 31, 2003. The increase
was principally due to cash generated by operations, cash received from employee
equity plans and a reduction in finance loans which was partially offset by
investment in property and equipment. Our cash and cash equivalents and
investment securities position increased during the three months ended March 31,
2004 by $12,611,000 to $85,748,000 from $$73,137,000 at December 31, 2003. This
is because the aggregate of cash provided by operating activities (including tax
benefits from exercise of stock options) of $12,850,000, cash provided by the
company's employee equity plans of $543,000 and net receipts of $628,000 under
finance loans exceeded the purchase of property and equipment of $1,410,000.
OPERATING ACTIVITIES: Our cash provided by operating activities tends
to increase over time because of increases in our net income. However, it is
subject to fluctuations, principally from changes in accounts receivable,
inventories, current liabilities and tax benefits from exercise of stock
options.
Normally the substantial majority of our accounts receivable are
current or no more than thirty days past due. In recent years, the majority of
each quarter's sales have been in that last half of the quarter with the result
that the amount of accounts receivable reported as of the end of each quarter
tend to be higher than the amounts at other times during a quarter.
Accounts receivable decreased from $24,943,000 at December 31, 2003 to
$17,798,000 at March 31, 2004, or 29%; the decrease was principally because
revenue in the first quarter of 2004 was 25% less than revenue in the fourth
quarter of 2003.
We generally try to maintain a minimal amount of inventory of finished
goods and work in process, but will maintain larger amounts of components
(classified as raw material) acquired from third parties to avoid production
delays if deliveries by our suppliers are late. However, in order to avoid
production inefficiencies caused by fluctuating production levels, we have begun
to level out our production volumes and build finished goods of our standard
(non-custom) products to meet future orders. This may cause fluctuations in our
quarterly inventory levels.
Inventories increased $2,512,000, or 74%, from $3,398,000 at December
31, 2003 to $5,910,000 at March 31, 2004 principally because of our decision to
increase our production volumes beyond current orders and increase our finished
goods inventories in anticipation of higher revenues for the second half of
2004. It caused our finished good inventory to increase in the first quarter of
2004, and we anticipate an additional increase in the second quarter of 2004,
but we expect finished good inventories to return to historical levels by the
end of 2004.
Our current liabilities tend to fluctuate based on the timing of when
liabilities are incurred and paid. The largest single source of fluctuation has
been income tax liabilities, and those fluctuations are generally a function of
the timing and amount of estimated tax payments in relation to actual tax
liabilities.
17
The tax benefits from the exercise of stock options, which we believe
is more properly related to the sale of our stock which is a financing activity,
fluctuates based principally on when employees choose to exercise their vested
stock options. Tax benefits from the exercise of stock options in the first
quarter of 2004 were $122,000 on the exercise of options to acquire 18,211
shares as compared to $3,000 in the first quarter of 2003 on the exercise of
options to acquire 500 shares.
We expect that sales of our products will grow in the second half of
2004. If sales increase, accounts receivable and inventories are expected to
increase as well. As a result of these and other factors, we expect the use of
working capital to fund our operations to continue to increase.
INVESTING ACTIVITIES: During the first quarter of 2004 we used cash of
$11,382,000 in investing activities, comprised primarily of the purchase of
liquid investments of $10,600,000 utilizing cash generated by operations in
excess of other investing needs.
Capital expenditures were at a relatively high rate in 2003,
principally because of our expansion in Mexico, including an electron-beam
sterilizer, and investment in molds, molding equipment, automated assembly
equipment, computers and software.
Upon completing an evaluation of the design and capacity of our
manufacturing facilities, we estimate that our current facilities will be
adequate through 2004, but that production after 2004 may require additional
clean room facilities for molding and automated assembly. We expect to decide in
the future how to meet the need for any additional facilities and the location
of additional clean room facilities for molding and automated assembly.
Capital expenditures in the first quarter 2004 were $1,410,000
principally to maintain capacity. We currently estimate that capital
expenditures for the remainder 2004 will be approximately $4,600,000, bringing
the year total to approximately $6,000,000 and will be paid from cash we
generate from operations. We expect the $6 million will be spent on molds,
molding equipment and automated assembly equipment, computers and software to
maintain current capacity including targeted growth for 2004. Of those amounts,
approximately $500,000 was committed under contracts at March 31, 2004, and we
expect to commit the balance in 2004. Amounts of spending are estimates and
actual spending may substantially differ from those amounts.
ICU Finance, Inc. is a wholly owned consolidated subsidiary that we
established in 2002 as a licensed commercial lender to provide financing to
companies involved in distribution of healthcare products and provision of
healthcare services. Loans are made only to credit-worthy healthcare entities
and are fully secured by real and personal property. At March 31, 2004, it had
$8,279,000 in loans outstanding. Scheduled maturities are: remainder of 2004
$3,413,000; 2005 $1,228,000; 2006 $1,191,000; 2007 $1,168,000 and 2008
$1,279,000. Weighted average maturity (principal and interest) at March 31, 2004
was 1.5 years and the weighted average interest rate was 5.5%. In October 2003,
we discontinued new lending activities. We will honor existing lending
commitments. The maximum that can be borrowed under all commitments, including
amounts outstanding, was approximately $8,500,000 at March 31, 2004. This is
down from almost $13,000,000 at the end of the fourth quarter 2003 primarily due
to the expiration of lending agreements.
FINANCING ACTIVITIES: Cash provided by stock options and the employee
stock purchase plan, including tax benefits, was $665,000 in the first quarter
of 2004 as compared to $284,000 in the first quarter of 2003: options were
exercised on 18,211 shares in the first quarter of 2004 as compared with 500 in
the first quarter of 2003.
18
We spent $8,649,000 to acquire shares of our common stock in the first
quarter of 2003, but did not acquire any shares in the first quarter of 2004. We
may purchase our shares in the future. However, future acquisitions, if any,
will depend on market conditions and other factors.
We have a large cash and liquid investment position generated from
profitable operations and stock sales, principally from the exercise of employee
stock options. We maintain this position to fund our growth, meet increasing
working capital requirements, fund capital expenditures, and potentially to take
advantage of acquisition opportunities that may arise. Our primary investment
goal is capital preservation, as further described in Item 3. Quantitative and
Qualitative Disclosures about Market Risk, our liquid investments have very
little credit risk or market risk.
OFF BALANCE SHEET ARRANGEMENTS
In the normal course of business, we have agreed to indemnify officers
and directors of the Company to the maximum extent permitted under Delaware law
and to indemnify customers as to certain intellectual property matters related
to sales of our products. There is no maximum limit on the indemnification that
may be required under these agreements. We have never incurred, nor do we expect
to incur, any liability for indemnification. Except for indemnification
agreements, we do not have any "off balance sheet arrangements".
CONTRACTUAL OBLIGATIONS
We have the following contractual obligations of approximately the
following amounts. These amounts exclude purchase orders for goods and services
for current delivery; we do not have any long-term purchase commitments for such
items.
Payments due: less than 1 year from
Total March 31, 2004
----- --------------
Property and equipment $500,000 $500,000
========= =========
FORWARD LOOKING STATEMENTS
- --------------------------
Various portions of this Report, including this Management's Discussion
and Analysis, describe trends in our business and finances that we perceive and
state some of our expectations and beliefs about our future. These statements
about the future are "forward looking statements," and we identify them by using
words such as "believe," "expect," "estimate," "plan," "will," "continue,"
"could," may," and by similar expressions and statements about aims, goals and
plans. The forward looking statements are based on the best information
currently available to us and assumptions that we believe are reasonable, but we
do not intend the statements to be representations as to future results. They
include, among other things, statements about:
o future operating results and various elements of operating results,
including future expenditures on sales and marketing and product
development, sales and unit volumes of products, future license, royalty
and revenue share income, production costs, gross margins, SG&A, and R&D
expense, new product introductions, changes in working capital items such
as receivables and inventory, selling prices and income taxes;
o factors affecting operating results, such as shipments to specific
customers, expansion in international markets, selling prices, the market
shift to needleless technology, future increases or decreases in sales of
certain products and in certain markets and distribution channels, impact
of safety legislation, increases in systems capabilities, introduction and
sales of new products, manufacturing efficiencies, unit manufacturing
19
costs, acquisition and use of production equipment and expansion of
facilities and assembly capacity, expansion of markets and the need for
additional facilities, business seasonality and fluctuations in quarterly
results, customer ordering patterns and warranty claims, rebates and
returns;
o new or extended contracts with manufacturers and buying organizations, and
dependence on a small number of customers, effect of Abbott's spin-off of
its Hospital Products Division, effect of contract amendments with Hospira,
ability to replace distributors, and the outcome of our strategic
initiatives;
o regulatory approval and outcome of litigation; competitive and market
factors, including continuing development of competing products by other
manufacturers, consolidation of the healthcare provider market and downward
pressure on selling prices; and working capital requirements, changes in
accounts receivable and inventories, current liabilities, capital
expenditures, acquisitions of other businesses or product lines,
indemnification liabilities, contractual liabilities and common stock
repurchases.
The kinds of statements described above and similar forward looking
statements about our future performance are subject to a number of risks and
uncertainties which one should consider in evaluating the statements. First, one
should consider the factors and risks described in the statements themselves.
Those factors are uncertain, and if one or more of them turn out differently
than we currently expect, our operating results may differ materially from our
current expectations.
Second, one should read the forward looking statements in conjunction
with the Risk Factors in our Current Report on Form 8-K to the Securities and
Exchange Commission dated February 15, 2002 which is incorporated by reference.
Third, our actual future operating results are subject to other
important factors that we cannot predict or control, including among others the
following:
o general economic and business conditions;
o the effect of price and safety considerations on the healthcare
industry;
o competitive factors, such as product innovation, new technologies,
marketing and distribution strength and price erosion;
o unanticipated market shifts and trends;
o the impact of legislation affecting government reimbursement of
healthcare costs;
o changes by our major customers and independent distributors in their
strategies that might affect their efforts to market our products;
o unanticipated production problems; and
o the availability of patent protection and the cost of enforcing and of
defending patent claims.
We disclaim any obligation to update the statements or to announce publicly the
result of any revision to any of the statements contained herein to reflect
future events or developments.
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
- ------------------------------------------------------------------
We have a portfolio of corporate preferred stocks and
federal-tax-exempt state and municipal government debt securities. The
securities are all "investment grade" and we believe that we have virtually no
exposure to credit risk. Dividend and interest rates reset at auction for most
of the securities from between seven and forty-nine day intervals, with some
longer but none beyond twelve months, so we have very little market risk, that
is, risk that the fair value of the security will change because of changes in
market interest rates; they are readily saleable at par at auction dates, and
can normally be sold at par between auction dates.
20
Our future earnings are subject to potential increase or decrease
because of changes in short-term interest rates. Generally, each one-percentage
point change in the discount rate will cause our overall yield to change by
two-thirds to three-quarters of a percentage point, depending upon the relative
mix of federal-tax-exempt securities and corporate preferred stocks in the
portfolio and market conditions specific to the securities in which we invest.
At March 31, 2004 we had outstanding commercial loans of approximately
$8,297,000. Loans are made only to credit worthy parties and are fully secured
by real and personal property. We plan to hold the loans until maturity or
payoff. Maturities are five years or less and the weighted average maturity
(principal and interest payments) is 1.5 years. Because of the relatively small
amount of the commercial loans, market risk is not significant to our financial
statements.
We do not have any significant foreign currency risk. Sales to foreign
distributors are all denominated in U.S. dollars. Cash and receivables in
entities outside the United States, principally in Mexico and Italy, which are
denominated in foreign currency are insignificant and are generally offset by
accounts payable in the same foreign currency.
ITEM 4. CONTROLS AND PROCEDURES
- ---------------------------------
Our principal executive officer and principal financial officer have
concluded, based on their evaluation of our disclosure controls and procedures
(as defined in Regulations 13a-14(c) and 15a-14(c) under the Securities Exchange
Act of 1934) as of the end of the period covered by this report, that our
disclosure controls and procedures are effective to ensure that the information
we are required to disclose in the reports that we file or submit under the
Exchange Act is accumulated and communicated to our management, including our
principal executive officer and principal financial officer, as appropriate to
allow timely decisions regarding required disclosure and that such information
is recorded, processed, summarized and reported within the time periods
specified in the rules and forms of the Securities Exchange Commission. There
were no significant changes in our internal controls or in other factors that
could significantly affect our internal controls subsequent to the date of the
principal executive officer's and principal financial officer's evaluation,
including any corrective actions with regard to significant deficiencies and
material weaknesses.
21
PART II
OTHER INFORMATION
ITEM 1. LEGAL PROCEEDINGS
- --------------------------
In an action filed August 21, 2001 entitled ICU Medical, Inc. v. B
Braun Medical, Inc. pending in the United States District Court for the Northern
District of California, we allege that B. Braun infringes ICU's patent by the
manufacture and sale of its UltraSite medical connector. On December 30, 2003,
we were awarded an additional patent and on December 30, 2003 we filed an
additional action against B. Braun for patent infringement and moved to amend
the 2001 action to include that allegation. The 2001 action has since been
amended to include our claim of infringement of the additional patent. We seek
monetary damages and injunctive relief and intend to vigorously pursue this
matter. The outcome of this matter cannot be determined at this time
We are from time to time involved in various other legal proceedings,
either as a defendant or plaintiff, most of which are routine litigation in the
normal course of business. We believe that the resolution of the legal
proceedings in which we are involved will not have a material adverse effect on
our financial position or results of operations.
ITEM 2. CHANGES IN SECURITIES
- ------------------------------
Inapplicable
ITEM 3. DEFAULT UPON SENIOR SECURITIES
- ---------------------------------------
Inapplicable
ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS
- ------------------------------------------------------------
Inapplicable
ITEM 5. OTHER INFORMATION
- --------------------------
None
ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K
- -----------------------------------------
(a) Exhibits:
Exhibit 31: Certifications of Chief Executive Officer and Chief Financial
Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
Exhibit 32: Certifications of Chief Executive Officer and Chief Financial
Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
(b) Reports on Form 8-K:
The Registrant filed the following Report on Form 8-K during the quarter for
which this Report is filed:
Items 5 and 7 - January 15, 2004
Items 7 and 12 - February 2, 2004
22
Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
ICU Medical, Inc.
(Registrant)
/s/ Francis J. O'Brien Date: May 5, 2004
- ----------------------
Francis J. O'Brien
Chief Financial Officer
(Principal Financial Officer)
/s/ Scott E. Lamb Date: May 5, 2004
- -----------------
Scott E. Lamb
Controller
(Principal Accounting Officer)
23